All In Biotech

Drug Trial Radar · NCT03123406

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)

Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

750

Actual

Start

Apr 19, 2017

Primary completion

Apr 20, 2019

Study completion Sep 6, 2019

Sponsor

Sponsor type
Industry
First posted
Apr 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2. To explore the impact of Cinacalcet HCL using on the combined use of drugs; 3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in real-world period from 33rd to 52nd week.

Conditions

  • Hyperparathyroidism; Secondary, Renal

Interventions

  • Cinacalcet HClDrug

    Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compared with baseline data, the proportion of subjects reaching iPTH target at 20th weekTime frame: 20 weeks
  2. Compared with baseline data, the proportion of subjects reaching iPTH target at 32nd weekTime frame: 32 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Jinling Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.